GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demand States ask for more guidance from HHS on when COVID-19 emergency will end In biopharma VC world, what does it mean to take a 'leap'? For Leaps by Bayer, it's 'fewer, but maybe bigger bets' Exact Sciences posts early positive data from its next-generation Cologuard home screening test Fierce JPM Week: Bristol Myers' next-gen autoimmune med not just another JAK drug, exec says Fierce JPM Week: How 23andMe plans to harness its massive database to further its ambitions in drug development Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water Apple partner Rockley Photonics’ wearable blood pressure sensors clear pilot study You say Trintellix, I say Brintellix: Why a drug name in the US won't always translate across the pond CVS Health and Uber Health partner on free medical transportation to reduce barriers to care Mirati's adagrasib spurs 41% response in pancreatic, GI tumors, scoring points where KRAS leader Amgen hasn't gone BD unveils high-throughput cell sorter that merges fluorescence with visual imaging Featured Story | By Angus Liu GlaxoSmithKline and Vir Biotechnology are rushing to speed up production of their COVID-19 therapy, now that they're the only companies with an antibody that appears to be truly effective against omicron. read more |
| |
|---|
|
Top Stories By Robert King State officials are asking for more time and predictability when the COVID-19 public health emergency ends and when Medicaid eligibility redeterminations are expected to start. read more By Kyle LaHucik Sparking innovation at a Big Pharma with a 150-year history can be difficult, so sometimes it takes some outside perspective to get the ball rolling. That's where Leaps by Bayer comes in. read more By Conor Hale Working with the Mayo Clinic to improve its accuracy, the updated version could result in fewer unnecessary recommendations for follow-up colonoscopies, the company said. read more By Eric Sagonowsky After a high-profile study turned up safety risks for Pfizer's JAK inhibitor Xeljanz last year, the FDA put the entire class under a microscope—and it only recently went back to granting new approvals in that class. Bristol Myers Squibb, meanwhile, has a new candidate that the company's chief medical officer says is safer than the other JAKs. read more By Heather Landi Drug development is expensive, can take years to complete and doesn't guarantee a novel therapy for treating disease. But consumer genetic testing company 23andMe is forging ahead to leverage its massive database of genetic data for research and to make and sell its own therapies. read more By Annalee Armstrong Alnylam executives are heralding the replication of data between approved medicine Onpattro and the investigational treatment vutrisiran, which the company is trying to position as an easier-to-administer, next-generation treatment for transthyretin-mediated amyloidosis. Analysts, however, noted a few subtle differences where vutrisiran differed from the approved medicine. read more By Conor Hale Sensor maker Rockley Photonics reported that a pilot study of its wrist-worn device was able to measure a person’s blood pressure without the squeeze of a cuff. read more By Ben Adams As a British citizen living in England but writing on American drug names, I’m in the perfect position to know that many drugs approved in Europe and the U.K. can have very different names from those in the U.S. read more By Rebecca Torrence CVS Health is teaming up with Uber Health, the ride-sharing giant's healthcare arm, to offer free rides to medical care, work and education in high-risk communities. read more By Kyle LaHucik Mirati Therapeutics' KRAS drug adagrasib led to a 41% response rate in patients with pancreatic and other gastrointestinal tumors, the latest in the biotech's efforts to eke out an edge against the big winner in the drug class, Amgen. read more By Conor Hale A new high-speed cell sorting technology could help do more than find the proverbial needle in the haystack, but also categorize each individual strand of hay itself. read more |
